Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Porta

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Physics in Medicine and Biology|October 30, 2025
AI-driven software for automated quantification of skeletal metastases and treatment response evaluation using whole-body diffusion-weighted MRI (WB-DWI) in advanced prostate cancerAntonio Candito, Matthew D Blackledge, Richard Holbrey, et al.
The Lancet. Oncology|February 4, 2021
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trialsAnanya Choudhury, Nuria Porta, Emma Hall, et al.
European Urology|January 6, 2020
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the TestisMichael Cullen, Robert Huddart, Johnathan Joffe, et al.
European Urology|May 16, 2022
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 TrialEmma Hall, Syed A Hussain, Nuria Porta, et al.
European Urology Oncology|May 13, 2026
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled TrialsWei Shen Tan, Ashish M Kamat, Rebecca Lewis, et al.
Blood Advances|July 8, 2026
AI derived Whole-Body MRI metrics in multiple myeloma patients reveal unique insights into body composition and outcomesNicolas Basty, Martin F Kaiser, Charlotte Pawlyn, et al.
British Journal of Cancer|January 5, 2021
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosisJessica M Winfield, Jennifer C Wakefield, James D Brenton, et al.
European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.
Blood Cancer Journal|July 17, 2025
Whole body MRI by MY-RADS for imaging response assessment in multiple myelomaChristina Messiou, Nuria Porta, Dow-Mu Koh, et al.
European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Physics in Medicine and Biology|October 30, 2025
AI-driven software for automated quantification of skeletal metastases and treatment response evaluation using whole-body diffusion-weighted MRI (WB-DWI) in advanced prostate cancerAntonio Candito, Matthew D Blackledge, Richard Holbrey, et al.
The Lancet. Oncology|February 4, 2021
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trialsAnanya Choudhury, Nuria Porta, Emma Hall, et al.
European Urology|January 6, 2020
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the TestisMichael Cullen, Robert Huddart, Johnathan Joffe, et al.
European Urology|May 16, 2022
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 TrialEmma Hall, Syed A Hussain, Nuria Porta, et al.
European Urology Oncology|May 13, 2026
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled TrialsWei Shen Tan, Ashish M Kamat, Rebecca Lewis, et al.
Blood Advances|July 8, 2026
AI derived Whole-Body MRI metrics in multiple myeloma patients reveal unique insights into body composition and outcomesNicolas Basty, Martin F Kaiser, Charlotte Pawlyn, et al.
British Journal of Cancer|January 5, 2021
Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosisJessica M Winfield, Jennifer C Wakefield, James D Brenton, et al.
European Urology|October 4, 2018
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)John D Kelly, Wei Shen Tan, Nuria Porta, et al.
Blood Cancer Journal|July 17, 2025
Whole body MRI by MY-RADS for imaging response assessment in multiple myelomaChristina Messiou, Nuria Porta, Dow-Mu Koh, et al.
European Urology Focus|July 30, 2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional SurveyDavid Lorente, Praful Ravi, Niven Mehra, et al.
Pageof 6